Crispr Therapeutics shares tumble after significant earnings miss
David A. Lorber, Chairman and CEO of PhenixFIN Corp (NASDAQ:PFX), has recently increased his stake in the company through a series of stock acquisitions. According to a recent SEC filing, Lorber purchased a total of 2,000 shares over several transactions conducted between March 3 and March 5, 2025. The transactions were executed at prices ranging from $53.29 to $54.35 per share, amounting to a total investment of $107,552. The timing appears strategic, as InvestingPro data shows PFX has delivered strong returns, with a 28% gain over the past year and a 10.6% increase year-to-date.
Following these acquisitions, Lorber’s direct ownership in PhenixFIN Corp stands at 142,145 shares. Additionally, Lorber holds indirect stakes through his spouse and the FrontFour Master Fund, Ltd., where he serves as a managing member and principal owner of the investment manager. The company, currently valued at $109.84 million, trades at an attractive P/E ratio of 6.66 and has demonstrated solid fundamentals with 7.21% revenue growth in the last twelve months.
These transactions reflect Lorber’s ongoing commitment to the company, as he continues to maintain a significant personal and indirect investment in PhenixFIN Corp. According to InvestingPro analysis, PFX shows strong recent performance, with additional insights and metrics available to subscribers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.